Artelo Biosciences, Inc 8-K, filed May 15, 2026
Artelo Biosciences, Inc. (ARTL)
About this 8-K
Artelo Biosciences, Inc filed this 8-K on May 15, 2026, reporting on events of May 11, 2026.
Items reported
- Item 1.02: Ended a material agreement
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of Company as specified in its charter) |
|
| |||
(State or other jurisdiction of incorporation) |
| (Commission File Number) |
| (IRS Employer Identification No.) |
|
| |
(Address of principal executive offices) |
| (Zip Code) |
| ( |
|
| (Company’s telephone number, including area code) |
|
_________________________________________________ |
(Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
| Trading Symbol(s) |
| Name of each exchange on which registered |
|
| The |
Indicate by check mark whether the Company is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging Growth Company
If an emerging growth company, indicate by check mark if the Company has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.02 Termination of a Material Definitive Agreement.
On May 11, 2026, Artelo Biosciences, Inc. (the “Company”) provided notice to R.F. Lafferty & Co., Inc. (“R.F. Lafferty”) of its election to terminate that certain At-The-Market Offering Agreement, dated July 18, 2025, by and between the Company and R.F. Lafferty (the “Sales Agreement”), which termination will be effective on May 18, 2026, in accordance with the terms of the Sales Agreement. Pursuant to the Sales Agreement, the Company was entitled to offer and sell, from time to time through R.F. Lafferty, shares of its common stock, par value $0.001 per share (the “Common Stock”), having an aggregate offering price of up to $6,500,000 in an at-the-market equity offering program. Through May 11, 2026, the Company had sold an aggregate of 50,858 shares of Common Stock pursuant to the Sales Agreement, resulting in gross proceeds of $451,526.95.
2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 15, 2026 | ARTELO BIOSCIENCES, INC. |
| |
|
|
| |
| /s/ Gregory D. Gorgas |
| |
| Name: | Gregory D. Gorgas |
|
| Title: | Chief Executive Officer and President |
|
3 |